

A point-by-point response to reviewers' comments:

Reviewers' comments:

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: Dear authors thank you for your good review, you can add some information about monoclonal ab and T cell engineering end of the review immunomodulator section, also the table about new drugs.

We thank the reviewer for his/her comments and for giving us the opportunity to improve our job. Information about monoclonal antibodies is already described in section 4.3.1.1 (HBV entry inhibitors). For better understanding, we have relocated the section on immunomodulatory therapy. We also added a new paragraph on Tcell engineering. However, we did not include it in the table because the clinical trials are still in very early phases.

Reviewer #2:

Scientific Quality: Grade A (Excellent)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (High priority)

Specific Comments to Authors: Authors have written a detailed and exhaustive review on hepatitis B. It is very interesting and they have done a wonderful job in digging all aspects of hepatitis B since beginning. I have few suggestions.

1. They can improve the title which includes something like "Journey of Dane particle to cccDNA."

We thank the reviewer for giving us the opportunity to improve our work. We have changed the title according to his/her recommendation.

2. In conclusion they should give guidance statement for what they feel best on new serum markers and therapeutics which are expected to get approval in near future.

We would like to thank the reviewer for his/her comments. We have added a new paragraph in section 4.2. on serum biomarkers. However, we consider that with the information that we have now, it is difficult to make a "recommendation" or a suggestion of which treatments we consider best in clinical practice, so we would prefer not to make a statement on this point.